Header

UZH-Logo

Maintenance Infos

First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands


Rupp, Niels J; Umbricht, Christoph A; Pizzuto, Daniele A; Lenggenhager, Daniela; Töpfer, Antonia; Müller, Julian; Mühlematter, Urs Jacob; Ferraro, Daniela A; Messerli, Michael; Morand, Grégoire B; Huber, Gerhard F; Eberli, Daniel; Schibli, Roger; Müller, Cristina; Burger, Irene A (2019). First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. Journal of Nuclear Medicine, 60(9):1270-1276.

Abstract

The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, as therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to allow the finding of solutions to reduce toxicity. The aim of this study was to investigate on whether or not the accumulation of PSMA-targeting radioligands in submandibular glands (SMG) can be explained with PSMA expression levels using the methods of autoradiography (ARG) and immunohistochemistry (IHC). Methods: All patients gave written informed consent for further utility of the biological material. SMG of 9 patients, pancreatic tissue of 4 patients and prostate cancer (PCA) lesions of 9 patients were analyzed. Fresh tissue specimen were analyzed by means of PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system - IRS) and ARG using 177Lu-PSMA-617 (with quantification of the relative signal intensity compared to a PSMA-positive standard). The SUVmax in salivary glands, pancreas and PCA tissues were quantified in 60 clinical 68Ga-PSMA-11 PET scans for recurrent disease, as well as the 9 primary tumors selected for ARG and IHC. Results: PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS 70–300) as well as in ARG (1.33 – 21.98%). This variability on PCA tissue could also be observed in 68Ga-PSMA-11 PET (SUVmax 4.4-16) with a significant correlation between ARG and SUVmax (P < 0.001, R2 = 0.897). On IHC, ARG and 68Ga-PSMA-11 PET, the pancreatic tissue was negative (IRS = 0, ARG = 0.1±0.05%, SUVmax of 3.1±1.1). The SMG tissue displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS 10-15) and a minimal signal on ARG (1.3±0.9%). In contrast, all SMG showed a high 68Ga-PSMA-11 accumulation on PET scans (SUVmax 23.5±5.2). Conclusion: Our results indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to a high PSMA expression levels determined using ARG and IHC. These findings provide evidence, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-mediated uptake.

Abstract

The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, as therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to allow the finding of solutions to reduce toxicity. The aim of this study was to investigate on whether or not the accumulation of PSMA-targeting radioligands in submandibular glands (SMG) can be explained with PSMA expression levels using the methods of autoradiography (ARG) and immunohistochemistry (IHC). Methods: All patients gave written informed consent for further utility of the biological material. SMG of 9 patients, pancreatic tissue of 4 patients and prostate cancer (PCA) lesions of 9 patients were analyzed. Fresh tissue specimen were analyzed by means of PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system - IRS) and ARG using 177Lu-PSMA-617 (with quantification of the relative signal intensity compared to a PSMA-positive standard). The SUVmax in salivary glands, pancreas and PCA tissues were quantified in 60 clinical 68Ga-PSMA-11 PET scans for recurrent disease, as well as the 9 primary tumors selected for ARG and IHC. Results: PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS 70–300) as well as in ARG (1.33 – 21.98%). This variability on PCA tissue could also be observed in 68Ga-PSMA-11 PET (SUVmax 4.4-16) with a significant correlation between ARG and SUVmax (P < 0.001, R2 = 0.897). On IHC, ARG and 68Ga-PSMA-11 PET, the pancreatic tissue was negative (IRS = 0, ARG = 0.1±0.05%, SUVmax of 3.1±1.1). The SMG tissue displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS 10-15) and a minimal signal on ARG (1.3±0.9%). In contrast, all SMG showed a high 68Ga-PSMA-11 accumulation on PET scans (SUVmax 23.5±5.2). Conclusion: Our results indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to a high PSMA expression levels determined using ARG and IHC. These findings provide evidence, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-mediated uptake.

Statistics

Citations

Dimensions.ai Metrics
58 citations in Web of Science®
60 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

248 downloads since deposited on 15 Mar 2019
24 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Otorhinolaryngology
04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
04 Faculty of Medicine > University Hospital Zurich > Urological Clinic
04 Faculty of Medicine > University Hospital Zurich > Clinic for Nuclear Medicine
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Radiology, Nuclear Medicine and Imaging
Uncontrolled Keywords:Radiology Nuclear Medicine and Imaging, Prostate cancer, Prostate-Specific Membrane Antigen, 177Lu-PSMA-617, 68Ga-PSMA-11, Positron Emission Tomography, immuno-histochemistry, autoradiography
Language:English
Date:1 September 2019
Deposited On:15 Mar 2019 12:59
Last Modified:04 Dec 2023 08:01
Publisher:Society of Nuclear Medicine
ISSN:0161-5505
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.2967/jnumed.118.222307
PubMed ID:30737300
  • Content: Accepted Version